Objectives This study sought to estimate and compare the aggregate treatment benefit of
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: High-sensitivity assays for cardiac troponin T (hs-cTnT) are …

Aims Natriuretic peptide-guided (NP-guided) treatment of heart failure has been tested
against standard clinically guided care in multiple studies, but findings have been limited by …

Background There is currently no objective practical guide to intensity of drug treatment for
individuals with heart failure. We hypothesised that pharmacotherapy guided by plasma …

Background—Newly discovered circulating peptides, N-terminal pro–brain natriuretic
peptide (N-BNP) and adrenomedullin (ADM), were examined for prediction of cardiac …

Background—A recent landmark report has demonstrated that plasma B-type natriuretic
peptide (BNP) measured in acute coronary syndromes independently predicts mortality …

OBJECTIVE Human brain natriuretic peptide‐32 (BNP)(ie proBNP (77–108)), the mature
form of BNP and secreted predominantly by the cardiac ventricle, is formed from a high …

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused
by mutations in the SMN1 gene that result in a deficiency of SMN protein. One approach to …

Objectives: The purpose of this study was to determine whether a new accelerated
diagnostic protocol (ADP) for possible cardiac chest pain could identify low-risk patients …

Objectives: The purpose of this study was to compare the effects of N-terminal pro–B-type
natriuretic peptide (NT-proBNP)-guided therapy with those of intensive clinical management …